%0 Journal Article
%T Infliximab-induced intertriginous psoriasis in patient with Crohn's desease
%A Federica Mola
%A Alberico Motolese
%J Dermatology Reports
%D 2011
%I PAGEPress Publications
%R 10.4081/dr.2011.e40
%X Tumor necrosis factor-¦Á (TNF¦Á) inhibition is an effective treatment of moderate-to-severe psoriasis and other diseases (rheumatoid arthritis, ankylosing spondylitis, psoriasis or Crohn¡¯s disease). We report a case of a 32- years-old patient affected by Crohn¡¯s disease since the age of 25 who started infliximab infusion after four years of treatment with prednisone and azathioprine per os without improvement. After the fifth infusion of infliximab, he developed a form of intertriginous psoriasis which was approached with topical steroid cream. The patient never presented psoriasis in the past. New onset of psoriasis in patients without history for skin diseases (as in our case) is a quite uncommon complication of TNF¦Á inhibitor therapy. The increased production of IFN¦Á during TNF¦Á inhibitor therapy is a possible pathophysiologic explanation for this paradoxical effect of the anti-TNF¦Á.
%K tumor necrosis factor ¦Á
%K psoriasis
%K crohn¡¯s disease
%U http://www.pagepress.org/journals/index.php/dr/article/view/3203